SERUM SERIAL NUMBER 2019 SERIAL

This study was a continuation of previous publication. The patientвЂ™s blood was drawn with standard procedures to obtained serum and examined both electrolytes and miRNA. About 52 patients that meet inclusion criteria from our previous study were included. This study was a cohort retrospective study. Materials and methods Study design and participant We hope that abnormal findings of both indicators should be anticipated to the poor outcome in lung cancer.

SERUM SERIAL NUMBER 2019 SERIAL

Therefore, we consider continuing our previous study to evaluate the correlation between electrolytes and serial miRNAs to prove that there is the molecular basis that underlying electrolytes disturbances in NCLC patients. Early recognition and proper correction of abnormal electrolytes are very important in cancer management.Д«oth miRNA and electrolytes have an important role to show us the outcome of cancer patients. This is one of the signs related to the poor outcome since the altered electrolyte could be worsening the patient condition.

The electrolyte disturbance was suggested as the effect of the cancer process itself, called the paraneoplastic process. Д¬ancer patients often experience abnormalities in the serum electrolytes. Our previous study showed that several miRNA expressions, such as miR-34, miR-222, miR-148, and miR-155, have predictive roles in lung cancer, especially NSCLC. More than two thousand types of miRNA have been found in humans that target at least 60% mRNA. There is non-coding small RNA, called micro RNA (miRNA), that play the role to decrease the protein expression of the targeted gene by repressing the translation process or degrading messenger RNA (mRNA). Since the very high mortality caused by lung cancer, more precision and sensitive therapy among non-small cell lung carcinoma (NSCLC) patients is needed.

This high mortality results from the advanced stage as well as the resistance to therapy. According to data from Dharmais National Cancer Hospital, lung cancer takes first place among others cancer for causing death in men and non-small cell carcinoma lung cancer (NSCLC) constitutes 85% of all lung cancer cases. Lung cancer is the most common cause of cancer-related death among men in the world.

Serum serial number 2019